Rumalon, 1 ml 25 pcs

Degenerative-dystrophic joint diseases:

– gonarthrosis;

– arthrosis of the interfinger joints;

– coxarthrosis;

– spondylosis;

– spondyloarthritis;

– meniscopathy;

– chondromalacia of the patella.

Indications

Degenerative-dystrophic diseases of the joints:

– gonarthrosis;

– arthrosis of the interdigital joints;

– coxarthrosis;

– spondylosis;

— spondyloarthrosis;

– meniscopathy;

– chondromalacia of the patella.

Pharmacological effect

A drug that regulates metabolism in cartilage tissue

Special instructions

When used simultaneously with indirect anticoagulants, antiplatelet agents and fibrinolytics, frequent monitoring of blood coagulation parameters is necessary.

Impact on the ability to drive vehicles and machinery

The use of the drug does not affect the ability to perform potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions (driving vehicles, working with moving mechanisms, working as a dispatcher and operator).

Active ingredient

Glycosaminoglycan-peptide complex

Composition

1 amp. contains glycosaminoglycan-peptide complex 1 ml

Contraindications

– hypersensitivity to the components of the drug;

– rheumatoid arthritis;

— age up to 18 years;

– pregnancy;

– period of breastfeeding;

– use in women of reproductive age who do not comply with reliable methods of contraception.

Side Effects

Determination of the frequency of adverse reactions (according to WHO classification): very often (≥1/10), often (from ≥1/100 to <1/10), infrequently (from ≥1/1000 to <1/100), rarely (from ≥1/10,000 to <1/1000), very rarely (<1/10,000), frequency unknown (set the frequency based on available data occurrence was not possible).

From the immune system: rarely – allergic reactions, incl. anaphylactoid reactions, anaphylactic shock.

If these or any other side effects occur, the patient must stop using the drug and inform the attending physician.

Interaction

The drug Rumalon can be used simultaneously with NSAIDs and corticosteroids.

When used simultaneously with indirect anticoagulants, antiplatelet agents and fibrinolytics, their effect may be enhanced.

Overdose

To date, no cases of overdose have been registered.

Manufacturer

K.O.Rompharm Company S.R.L., Romania